June 16, 2022
Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial | Persistence of residual SARS-CoV-2 viral antigen and RNA in tissues of patients with long COVID-19 | Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19 | Rebound Phenomenon after Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease-2019 in High-Risk Persons | The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination